University of British Columbia

As a University of British Columbia (“UBC”) spin-off, BirchBioMed took on the significant challenge of developing FS2 and AI-001 as major therapeutic agents to be made available to millions of patients.

This is the best testimony of BirchBioMed capabilities and commitment, recognized by the most prestigious government research institution, to bring these therapeutics  to patients in dire need of novel solutions to address their diseases.

This highly significant achievement — coupled with extensive funding from Canada’s most prestigious government and private research institutions representing more than $6 million – are an index of this technology’s potential importance and potential incalculable impact on society. Its promise resulted in the vital milestone of successful completion of phase 1 clinical trials.